CKD and nonalcoholic fatty liver disease

American Journal of Kidney Diseases

Volumn 64, Issue 4, 2014, Pages 638-652

  Targher, Giovanni ^a   Chonchol, Michel B ^b   Byrne, Christopher D ^c,d  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d University of Southampton   (United Kingdom)

Author keywords

chronic kidney disease; metabolic syndrome; Nonalcoholic fatty liver disease; review; risk factors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; FIBRIC ACID DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; OMEGA 3 FATTY ACID; OXIDIZING AGENT; PROCOAGULANT;

ATHEROGENESIS; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; KIDNEY INJURY; MEDIATOR RELEASE; NONALCOHOLIC FATTY LIVER; NONHUMAN; REVIEW; TREATMENT INDICATION; COMPLICATION; EARLY INTERVENTION; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; PROCEDURES; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

DISEASE PROGRESSION; EARLY MEDICAL INTERVENTION; GLOMERULAR FILTRATION RATE; HUMANS; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84908128731     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.05.019     Document Type: Review

References (67)

1. N. Chalasani, Z. Younossi, and J.E. Lavine The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association Hepatology 55 2012 2005 2023
2. R. Loomba, and A.J. Sanyal The global NAFLD epidemic Nat Rev Gastroenterol Hepatol 10 2013 686 690
3. Q.M. Anstee, G. Targher, and C.P. Day Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis Nat Rev Gastroenterol Hepatol 10 2013 330 344
4. G. Targher, and C.D. Byrne Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications J Clin Endocrinol Metab 98 2013 483 495
5. G. Targher, C.P. Day, and E. Bonora Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease N Engl J Med 363 2010 1341 1350
6. G. Targher, M. Chonchol, G. Zoppini, C. Abaterusso, and E. Bonora Risk of chronic kidney disease in patients with nonalcoholic fatty liver disease: is there a link? J Hepatol 54 2011 1020 1029
7. M.J. Armstrong, L.A. Adams, A. Canbay, and W.K. Syn Extra-hepatic complications of nonalcoholic fatty liver disease Hepatology 59 2014 1174 1197
8. R. Hernaez, M. Lazo, and S. Bonekamp Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis Hepatology 54 2011 1082 1090
9. G.A. Michelotti, M.V. Machado, and A.M. Diehl NAFLD, NASH and liver cancer Nat Rev Gastroenterol Hepatol 10 2013 656 665
10. M.R. Charlton, J.M. Burns, R.A. Pedersen, K.D. Watt, J.K. Heimbach, and R.A. Dierkhising Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States Gastroenterology 141 2011 1249 1253
11. F. Nascimbeni, R. Pais, and S. Bellentani From NAFLD in clinical practice to answers from guidelines J Hepatol 59 2013 859 871
12. A.K. Singal, P. Guturu, B. Hmoud, Y.F. Kuo, H. Salameh, and R.H. Wiesner Evolving frequency and outcomes of liver transplantation based on etiology of liver disease Transplantation 95 2013 755 760
13. D.D.L Houlihan, M.J. Armstrong, and Y. Davidov Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: time to reconsider immunosuppression regimens? Liver Transpl 17 2011 1292 1298
14. E. Bonora, and G. Targher Increased risk of cardiovascular disease and chronic kidney disease in NAFLD Nat Rev Gastroenterol Hepatol 9 2012 372 381
15. M. Kurella, J.C. Lo, and G.M. Chertow Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults J Am Soc Nephrol 16 2005 2134 2140
16. D.E. Weiner, H. Tighiouart, and E.F. Elsayed The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD Am J Kidney Dis 51 2008 212 223
17. J. Kendrick, and M.B. Chonchol Non-traditional risk factors for cardiovascular disease in patients with chronic kidney disease Nat Clin Pract Nephrol 4 2008 672 681
18. F. Kronenberg Emerging risk factors and markers of chronic kidney disease progression Nat Rev Nephrol 5 2009 677 689
19. G. Targher, L. Bertolini, S. Rodella, G. Zoppini, G. Lippi, and C. Day Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients Diabetologia 51 2008 444 450
20. G. Targher, L. Bertolini, M. Chonchol, S. Rodella, G. Zoppini, and G. Lippi Nonalcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients Diabetologia 53 2010 1341 1348
21. S.T. Hwang, Y.K. Cho, and J.W. Yun Impact of NAFLD on microalbuminuria in patients with prediabetes and diabetes Intern Med J 40 2010 437 442
22. G. Targher, I. Pichiri, G. Zoppini, M. Trombetta, and E. Bonora Increased prevalence of chronic kidney disease in patients with type 1 diabetes and non-alcoholic fatty liver Diabet Med 29 2012 220 226
23. G. Li, W. Shi, H. Hug, Y. Chen, L. Liu, and D. Yin Nonalcoholic fatty liver disease associated with impairment of kidney function in nondiabetes population Biochem Med (Zagreb) 22 2012 92 99
24. J.C. Sirota, K. McFann, G. Targher, M. Chonchol, and D.I. Jalal Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994 Am J Nephrol 36 2012 466 471
25. A.L. Ahn, J.K. Choi, and M.N. Kim Non-alcoholic fatty liver disease and chronic kidney disease in Koreans aged 50 years or older Korean J Fam Med 34 2013 199 205
26. I. Mikolasevic, S. Racki, I. Bubic, I. Jelic, D. Stimac, and L. Orlic Chronic kidney disease and nonalcoholic fatty liver disease proven by transient elastography Kidney Blood Press Res 37 2013 305 310
27. G. Targher, L. Bertolini, S. Rodella, G. Lippi, G. Zoppini, and M. Chonchol Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis Clin J Am Soc Nephrol 5 2010 2166 2171
28. Y. Yilmaz, Y.O. Alahdab, and O. Yonal Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis Metabolism 59 2010 1327 1330
29. K. Yasui, Y. Sumida, and Y. Mori Nonalcoholic steatohepatitis and increased risk of chronic kidney disease Metabolism 60 2011 735 739
30. C.W. Park, N.T. Tsai, and L.L. Wong Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more Clin Transplant 25 2011 E606 E611
31. M.V. Machado, S. Gonçalves, F. Carepa, J. Coutinho, A. Costa, and H. Cortez-Pinto Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease Liver Int 32 2012 241 248
32. G. Targher, M. Chonchol, and L. Bertolini Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease J Am Soc Nephrol 19 2008 1564 1570
33. Y. Chang, S. Ryu, and E. Sung Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men Metabolism 57 2008 569 576
34. Y. Arase, F. Suzuki, and M. Kobayashi The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease Intern Med 50 2011 1081 1087
35. G. Targher, A. Mantovani, and I. Pichiri Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes Diabetes Care 37 2014 1729 1736
36. D.H. Lee, D.R. Jacobs, M. Gross, and M. Steffes Serum gamma-glutamyltransferase was differently associated with microalbuminuria by status of hypertension and diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Study Clin Chem 51 2005 1185 1191
37. S. Ryu, Y. Chang, D.I. Kim, W.S. Kim, and B.S. Suh Gamma-glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men Clin Chem 53 2007 71 77
38. L.A. Stevens, J. Coresh, T. Greene, and A.S. Levey Assessing kidney function - measured and estimated glomerular filtration rate N Engl J Med 8 2006 2473 2483
39. L.A. Stevens, J. Coresh, and H.I. Feldman Evaluation of the Modification of Diet in Renal Disease Study equation in a large diverse population J Am Soc Nephrol 18 2007 2749 2757
40. M.K. Badman, and J.S. Flier The adipocyte as an active participant in the energy balance and metabolism Gastroenterology 132 2007 2103 2115
41. S.E. Shoelson, L. Herrero, and A. Naaz Obesity, inflammation and insulin resistance Gastroenterology 132 2007 2169 2180
42. C.D. Byrne Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management Diabet Med 29 2012 1098 1107
43. G. Sabio, M. Das, and A. Mora A stress signaling pathway in adipose tissue regulates hepatic insulin resistance Science 322 2008 1539 1543
44. N.M.W. de Alwis, and C.P. Day Nonalcoholic fatty liver disease: the mist gradually clears J Hepatol 48 suppl 1 2008 S104 S112
45. H. Tilg, and A.R. Moschen Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis Hepatology 52 2010 1836 1846
46. G. Targher, M. Chonchol, L. Miele, G. Zoppini, I. Pichiri, and M. Muggeo Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome Semin Thromb Hemost 35 2009 277 287
47. G. Targher, L. Bertolini, and S. Rodella NASH predicts plasma inflammatory biomarkers independently of visceral fat in men Obesity (Silver Spring) 16 2008 1394 1399
48. N. Stefan, and H.U. Häring The role of hepatokines in metabolism Nat Rev Endocrinol 9 2013 144 152
49. J. Westerbacka, M. Kolak, and T. Kiviluoto Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects Diabetes 56 2007 2759 2765
50. D. Greco, A. Kotronen, and J. Westerbacka Gene expression in human NAFLD Am J Physiol Gastrointest Liver Physiol 294 2008 G1281 G1287
51. S. Sookoian, T.F. Gianotti, M.S. Rosselli, A.L. Burgueno, G.O. Castano, and C.J. Pirola Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease Atherosclerosis 218 2011 378 385
52. N. Deji, S. Kume, and S. Araki Structural and functional changes in the kidneys of high-fat diet-induced obese mice Am J Physiol Renal Physiol 296 2009 F118 F126
53. I.A. Bobulescu, M. Dubree, J. Zhang, P. McLeroy, and O.W. Moe Effect of renal lipid accumulation on proximal tubule Na/H exchange and ammonium secretion Am J Physiol Renal Physiol 294 2008 F1315 F1322
54. M.C. Foster, S.J. Hwang, S.A. Porter, J.M. Massaro, U. Hoffmann, and C.S. Fox Fatty kidney, hypertension, and chronic kidney disease: the Framingham Heart Study Hypertension 58 2011 784 790
55. F. Guebre-Egziabher, P.M. Alix, and L. Koppe Ectopic lipid accumulation: a potential cause for metabolic disturbances and a contributor to the alteration of kidney function Biochimie 95 2013 1971 1979
56. Z.A. Massy, P. Stenvinkel, and T.B. Drueke The role of oxidative stress in chronic kidney disease Semin Dial 22 2009 405 408
57. H. Vlassara, M. Torreggiani, J.B. Post, F. Zheng, J. Uribarri, and G.E. Striker Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging Kidney Int Suppl 114 2009 S3 S11
58. A.R. Moschen, V. Wieser, and H. Tilg Adiponectin: key player in the adipose tissue-liver crosstalk Curr Med Chem 19 2012 5467 5473
59. J.H. Ix, and K. Sharma Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK J Am Soc Nephrol 21 2010 406 412
60. G. Targher, and C.D. Byrne Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications Semin Thromb Hemost 39 2013 214 228
61. C.P. Day Clinical spectrum and therapy of non-alcoholic steatohepatitis Dig Dis 30 suppl 1 2012 69 73
62. V. Ratziu Pharmacological agents for NASH Nat Rev Gastroenterol Hepatol 10 2013 676 685
63. V.G. Athyros, K. Tziomalos, T.D. Gossios GREACE Study Collaborative Group Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis Lancet 376 2010 1916 1922
64. M.J. Tikkanen, R. Fayyad, O. Faergeman on behalf of the IDEAL Investigators Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels Int J Cardiol 168 2013 3846 3852
65. V. Ratziu, S. Caldwell, and B.A. Neuschwander-Tetri Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues Hepatology 52 2010 2206 2215
66. A.J. Sanyal, N. Chalasani, K.V. Kowdley for the NASH Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 362 2010 1675 1685
67. E. Scorletti, and C.D. Byrne Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease Annu Rev Nutr 33 2013 231 248